152 related articles for article (PubMed ID: 34508066)
1. Tripartite motif-containing 3 (TRIM3) enhances ER signaling and confers tamoxifen resistance in breast cancer.
Ye R; AiErken N; Kuang X; Zeng H; Shao N; Lin Y; Liu P; Wang S
Oncogenesis; 2021 Sep; 10(9):60. PubMed ID: 34508066
[TBL] [Abstract][Full Text] [Related]
2. TRIM3 facilitates estrogen signaling and modulates breast cancer cell progression.
Zhuang T; Wang B; Tan X; Wu L; Li X; Li Z; Cai Y; Fan R; Yang X; Zhang C; Xia Y; Niu Z; Liu B; Cao Q; Ding Y; Zhou Z; Huang Q; Yang H
Cell Commun Signal; 2022 Apr; 20(1):45. PubMed ID: 35392925
[TBL] [Abstract][Full Text] [Related]
3. Advances in the antitumor mechanisms of tripartite motif-containing protein 3.
Teng W; Ling Y; Liu Z; Jiang L; Fu G; Zhou X; Long N; Liu J; Chu L
J Cancer Res Clin Oncol; 2024 Feb; 150(2):105. PubMed ID: 38411731
[TBL] [Abstract][Full Text] [Related]
4. TRIM3 and TRIM16 as potential tumor suppressors in breast cancer patients.
Roshanazadeh MR; Adelipour M; Sanaei A; Chenane H; Rashidi M
BMC Res Notes; 2022 Sep; 15(1):312. PubMed ID: 36180926
[TBL] [Abstract][Full Text] [Related]
5. Tripartite motif-containing 3 (TRIM3) inhibits tumor growth and metastasis of liver cancer.
Huang XQ; Zhang XF; Xia JH; Chao J; Pan QZ; Zhao JJ; Zhou ZQ; Chen CL; Tang Y; Weng DS; Zhang JH; Xia JC
Chin J Cancer; 2017 Sep; 36(1):77. PubMed ID: 28950898
[TBL] [Abstract][Full Text] [Related]
6. The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer.
Liu SS; Li Y; Zhang H; Zhang D; Zhang XB; Wang X; Yu Y
Theranostics; 2020; 10(23):10729-10742. PubMed ID: 32929377
[No Abstract] [Full Text] [Related]
7. TRIM3 inhibits P53 signaling in breast cancer cells.
Wang X; Zhang Y; Pei X; Guo G; Xue B; Duan X; Dou D
Cancer Cell Int; 2020 Nov; 20(1):559. PubMed ID: 33292295
[TBL] [Abstract][Full Text] [Related]
8. MEL-18 loss mediates estrogen receptor-α downregulation and hormone independence.
Lee JY; Won HY; Park JH; Kim HY; Choi HJ; Shin DH; Kang JH; Woo JK; Oh SH; Son T; Choi JW; Kim S; Kim HY; Yi K; Jang KS; Oh YH; Kong G
J Clin Invest; 2015 May; 125(5):1801-14. PubMed ID: 25822021
[TBL] [Abstract][Full Text] [Related]
9. Tripartite motif-containing protein 3 plays a role of tumor inhibitor in cervical cancer.
Song Y; Guo Q; Gao S; Hua K
Biochem Biophys Res Commun; 2018 Apr; 498(3):686-692. PubMed ID: 29524410
[TBL] [Abstract][Full Text] [Related]
10. Tripartite-motif 3 represses ovarian cancer progression by downregulating lactate dehydrogenase A and inhibiting AKT signaling.
Cong Y; Cui X; Shi Y; Pan X; Huang K; Geng Z; Xu P; Ge L; Zhu J; Xu J; Jia X
Mol Cell Biochem; 2024 Feb; ():. PubMed ID: 38367118
[TBL] [Abstract][Full Text] [Related]
11. Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
Choi HJ; Joo HS; Won HY; Min KW; Kim HY; Son T; Oh YH; Lee JY; Kong G
J Natl Cancer Inst; 2018 Apr; 110(4):. PubMed ID: 29028222
[TBL] [Abstract][Full Text] [Related]
12. Divergent self-association properties of paralogous proteins TRIM2 and TRIM3 regulate their E3 ligase activity.
Esposito D; Dudley-Fraser J; Garza-Garcia A; Rittinger K
Nat Commun; 2022 Dec; 13(1):7583. PubMed ID: 36481767
[TBL] [Abstract][Full Text] [Related]
13. miR-4513 promotes breast cancer progression through targeting TRIM3.
Li Y; Zhu H; Wang J; Qian X; Li N
Am J Transl Res; 2019; 11(4):2431-2438. PubMed ID: 31105849
[TBL] [Abstract][Full Text] [Related]
14. Forkhead box o3a suppresses lipopolysaccharide-stimulated proliferation and inflammation in fibroblast-like synoviocytes through regulating tripartite motif-containing protein 3.
Wang M; Wu J; Zhou E; Chang X; Gan J; Cheng T
J Cell Physiol; 2019 Nov; 234(11):20139-20148. PubMed ID: 30980385
[TBL] [Abstract][Full Text] [Related]
15. IGF-1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER-positive breast cancer.
Kruger DT; Alexi X; Opdam M; Schuurman K; Voorwerk L; Sanders J; van der Noort V; Boven E; Zwart W; Linn SC
Int J Cancer; 2020 Apr; 146(8):2348-2359. PubMed ID: 31490549
[TBL] [Abstract][Full Text] [Related]
16. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
[TBL] [Abstract][Full Text] [Related]
17. Cross-talk between the ER pathway and the lncRNA MAFG-AS1/miR-339-5p/ CDK2 axis promotes progression of ER+ breast cancer and confers tamoxifen resistance.
Feng J; Wen T; Li Z; Feng L; Zhou L; Yang Z; Xu L; Shi S; Hou K; Shen J; Han X; Teng Y
Aging (Albany NY); 2020 Oct; 12(20):20658-20683. PubMed ID: 33098638
[TBL] [Abstract][Full Text] [Related]
18. Potential role of TRIM3 as a novel tumour suppressor in colorectal cancer (CRC) development.
Piao MY; Cao HL; He NN; Xu MQ; Dong WX; Wang WQ; Wang BM; Zhou B
Scand J Gastroenterol; 2016; 51(5):572-82. PubMed ID: 26691157
[TBL] [Abstract][Full Text] [Related]
19. Polycomb complex protein BMI1 confers resistance to tamoxifen in estrogen receptor positive breast cancer.
Ojo D; Lin X; Wu Y; Cockburn J; Bane A; Tang D
Cancer Lett; 2018 Jul; 426():4-13. PubMed ID: 29626519
[TBL] [Abstract][Full Text] [Related]
20. Wilms' tumor 1 suppressor gene mediates antiestrogen resistance via down-regulation of estrogen receptor-alpha expression in breast cancer cells.
Han Y; Yang L; Suarez-Saiz F; San-Marina S; Cui J; Minden MD
Mol Cancer Res; 2008 Aug; 6(8):1347-55. PubMed ID: 18708366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
